RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      검색결과 좁혀 보기

      선택해제

      오늘 본 자료

      • 오늘 본 자료가 없습니다.
      더보기
      • 무료
      • 기관 내 무료
      • 유료
      • KCI등재

        Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience

        Alice Indini,Lorenza Di Guardo,Carolina Cimminiello,Domenica Lorusso,Francesco Raspagliesi,Michele Del Vecchio 대한부인종양학회 2019 Journal of Gynecologic Oncology Vol.30 No.6

        Objective: immunotherapy with immune checkpoint inhibitors has become one of thestandard therapeutic modalities for patients with advanced melanoma. Melanoma of thefemale lower genital tract is a rare and aggressive disease, with poor long-term clinicaloutcomes. To date, no study evaluated the role of immunotherapy in metastatic melanoma ofthe lower genital tract. Methods: Data of women with metastatic melanoma of the lower genital tract wereprospectively collected. Survival outcomes over time was assessed using Kaplan-Meier model. Results: Seven cases of metastatic melanoma of the lower genital tract (vulva [n=2], vagina[n=4], and uterine cervix [n=1]) treated with immune checkpoint inhibitors are reviewed. Two patients had metastatic disease at diagnosis, while 5 patients developed metastaticdisease at a mean (standard deviation) time of 9.9 (±3.0) months from primary diagnosis. Four patients received an anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA4)(ipilimumab) and 3 received an anti-programmed cell death 1 (PD-1) (pembrolizumab[n=2], nivolumab [n=1]) therapy. The response rate to immunotherapy was 28.5%. Patientsreceiving an anti-PD-1 experienced a better progression-free survival than patients treatedwith anti-CTLA4 (p=0.01, log-rank test). Although not reaching statistical significance,overall survival was better in patients having an anti-PD-1 therapy in comparison to anti-CTLA4 (p=0.15, log-rank test). Conclusion: Results from our series confirm the poor prognosis of women with metastaticmelanoma of the lower genital tract, thus supporting the need of exploring newtreatment modalities. Further studies are warranted to improve knowledge on the role ofimmunotherapy in metastatic melanoma of the lower genital tract.

      연관 검색어 추천

      이 검색어로 많이 본 자료

      활용도 높은 자료

      해외이동버튼